However, during the last decade targeted therapies including BTKis, B-cell lymphoma 2 (BCL2) antagonists and phosphoinositide 3-kinase (PI3K) inhibitors entered the therapeutic scene and significantly improved the overall outcome for patients with TP53 aberration and advanced-phase CLL (23–25). The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.